Roche Posts Phase 2 Enicepatide Diabetes Win, Advancing A GLP-1/GIP Bid Beyond Obesity

Roche said its dual GLP-1/GIP receptor agonist enicepatide met the primary endpoints in a phase 2 trial in patients with Type 2 diabetes, adding glycemic-control data to earlier weight-loss results and strengthening the company’s case for the asset beyond obesity. The molecule, also called CT-388, came to Roche through its $2.7 billion acquisition of Carmot Therapeutics.

Enicepatide targets the same receptors as Eli Lilly’s tirzepatide, sold as Mounjaro and Zepbound, but Roche has pointed to the candidate’s dually biased mechanism as a differentiator that could prolong pharmacological activity. The new dataset is important because it tests that thesis in a population with Type 2 diabetes rather than obesity alone.

The data

HbA1c fell 2.65% in patients receiving the top, 24-mg weekly dose of enicepatide for 48 weeks. Roche described the result as supporting best-in-disease potential.

The company also reported secondary measures that it said were competitive, while noting the limits of cross-trial comparisons. Up to 90% of patients receiving enicepatide reached an HbA1c level of 6.5% or below. Sixty-two percent reached an HbA1c level of 5.7% or below.

Weight loss at Week 48 reached 15.5% at the high dose, which Roche said occurred “without a demonstrable plateau.” That language matters because it suggests the company believes longer studies could produce deeper weight loss.

Roche has not yet shared detailed safety and tolerability data. Consistent with other molecules in the class, enicepatide mostly caused mild-to-moderate gastrointestinal effects. Two percent of patients receiving the drug candidate discontinued because of adverse events, versus 0% in the placebo group.

The competitive picture

Roche compared its results with Lilly and Novo Nordisk programs, but the company also acknowledged that its endpoints were assessed eight weeks later than Lilly’s, preventing direct comparisons. Lilly reported HbA1c reductions of up to 1.8% at Week 40 in a phase 3 Mounjaro trial, and up to 1.94% at 40 weeks for investigational triple agonist retatrutide in a phase 3 trial. Novo reported a 1.6% decline at Week 30 in a phase 3 Ozempic study.

On weight loss, Lilly reported up to 15.3% at Week 40 for retatrutide. That leaves Roche with numerically competitive data, but not a clean basis for declaring superiority.

That distinction is commercially important. Earlier obesity data had already suggested enicepatide could compete on efficacy, but BMO Capital Markets analysts wrote in July that “Lilly’s retatrutide is likely to remain the preferred high-efficacy weight loss agent at this time.” The latest diabetes results improve Roche’s position, yet they do not remove the burden of proving differentiation in larger, later-stage studies.

What comes next

Roche is already running three phase 3 enicepatide trials in obesity, including two with global sites and one focused on China. The company plans to start a phase 3 glycemic-control program and cardiovascular outcomes trials in the first half of next year.

The signal in this readout is that Roche is no longer pitching enicepatide solely as another obesity entrant. By generating diabetes data that appear broadly competitive, the company is building a case for a fuller cardiometabolic franchise. Whether that becomes enough to shift market expectations will depend on detailed safety disclosure and how the phase 3 package compares on timelines and durability, not just on top-line efficacy.